SCHEMBL6317834

SCHEMBL6317834

[O+2].[O+2].[O+2].[O-]P([O-])([O-])=S.[O-]P([O-])([O-])=S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18227146 0.86
SCHEMBL7715777 0.86
SCHEMBL2638699 0.86
SCHEMBL4599756 0.86
SCHEMBL20581663 0.86
SCHEMBL3855818 0.86
SCHEMBL2278783 0.86
SCHEMBL3852808 0.86
SCHEMBL2638694 0.86
SCHEMBL708051 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425857-A1 Means and Methods for Chronic Wound Healing VIB VZW (BE) 2024-12-26 US disclosed
US-20240382506-A1 Means and Methods to Regulate Gut Dysbiosis UNIVERSITEIT GENT (BE) 2024-11-21 US disclosed
EP-4423269-A2 MEANS AND METHODS FOR CHRONIC WOUND HEALING VIB VZW (BE) 2024-09-04 EP disclosed
EP-3523433-B1 MEANS AND METHODS TO TREAT INFLAMMATORY DISEASES VIB VZW (BE) 2024-05-08 EP disclosed
EP-4355877-A1 MEANS AND METHODS TO REGULATE GUT DYSBIOSIS VIB VZW (BE) 2024-04-24 EP disclosed
WO-2023073046-A2 MEANS AND METHODS FOR CHRONIC WOUND HEALING VIB VZW (BE) 2023-05-04 WO disclosed
WO-2022263678-A1 MEANS AND METHODS TO REGULATE GUT DYSBIOSIS VIB VZW (BE) 2022-12-22 WO disclosed
US-11466270-B2 Means and methods to treat inflammatory diseases VIB VZW (BE) 2022-10-11 US disclosed
US-20220313697-A1 NEK6 Inhibition to Treat ALS and FTD KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2022-10-06 US disclosed
WO-2022199804-A1 NEK6 INHIBITION TO TREAT ALS AND FTD VIB VZW (BE) 2022-09-29 WO disclosed
EP-3976055-A1 COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING UVEAL MELANOMA Universiteit Gent (BE) 2022-04-06 EP disclosed
EP-3746555-B1 INHIBITION OF A LNCRNA FOR TREATMENT OF NEUROBLASTOMA UNIV GENT (BE) 2022-03-30 EP disclosed
US-6967247-B2 Deprotection of phosphorus in oligonucleotide synthesis ISIS PHARMACEUTICALS, INC. (US) 2005-11-22 US disclosed
US-6965041-B1 N-acylphosphoramidites and their use in oligonucleotide synthesis THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2005-11-15 US disclosed
US-6762298-B2 DEPROTECTING AN OLIGONUCLEOTIDE BY HEATING IN A FLUID, WHERE THE PHOSPHORUS ATOM IS O-PROTECTED WITH A THERMOLABILE GROUP SUCH AS (PYRROLIDIN-1-ONE-1-YL)ALKYL; SYNTHESIS OF OLIGONUCLEOTIDES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 2004-07-13 US disclosed
US-20040024194-A1 Deprotection of phosphorus in oligonucleotide synthesis ISIS PHARMACEUTICALS, INC. 2004-02-05 US disclosed
WO-2004009612-A1 DEPROTECTION OF PHOSPHORUS IN OLIGONUCLEOTIDE SYNTHESIS ISIS PHARMACEUTICALS, INC. (US) 2004-01-29 WO disclosed
EP-1163251-A1 N-ACYLPHOSPHORAMIDITES AND THEIR USE IN OLIGONUCLEOTIDE SYNTHESIS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2001-12-19 EP disclosed
US-20010044529-A1 Thermolabile phosphorus protecting groups, associated intermediates and methods of use GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2001-11-22 US disclosed
WO-2000056749-A1 N-ACYLPHOSPHORAMIDITES AND THEIR USE IN OLIGONUCLEOTIDE SYNTHESIS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2000-09-28 WO disclosed